Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy

Journal of Clinical Oncology

Volumn 20, Issue 7, 2002, Pages 1721-1728

  Edler, David ^a   Glimelius, Bengt ^a   Hallström, Maria ^a   Jakobsen, Anders ^a   Johnston, Patrick G ^a   Magnusson, Inger ^a   Ragnhammar, Peter ^a   Blomgren, Henric ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LEVAMISOLE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

ADJUVANTS, IMMUNOLOGIC; AGED; ANALYSIS OF VARIANCE; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LEUCOVORIN; LEVAMISOLE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0036534108     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.07.039     Document Type: Article

References (31)

1. Estimates of the worldwide mortality from 25 cancers in 1990
2. American Society of Clinical Oncology: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer
3. p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site
4. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer
5. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance
6. Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method
7. Thymidylate synthase expression: An independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer
8. Immunohistochemically detected thymidylate synthase in colorectal cancer: An independent prognostic factor of survival
9. Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: Implications for chemotherapeutic options and survival
10. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: An analysis of response and survival
11. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: Preliminary report from an ongoing trial
12. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy
13. Thymidylate synthase protein expression in advanced colon cancer: Correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil
14. Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine
15. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin
16. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors
17. Thymidylate synthetase: A target enzyme in cancer chemotherapy
18. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
19. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil - The North Central Cancer Treatment Group and the Mayo Clinic
20. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
21. Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer - The Nordic Gastrointestinal Tumor Adjuvant Therapy Group
22. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
23. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue
24. A generalized Wilcoxon test for comparing arbitrarily single-censored samples
25. Regression models and life-tables
26. Nonparametric estimation from incomplete observations
27. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer
28. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: Results from NSABP protocol R-01
29. The mesorectum in rectal cancer surgery: The clue to pelvic recurrence?
30. Recurrence and survival after total mesorectal excision for rectal cancer
31. Immunohistochemical determination of thymidylate synthase in colorectal cancer: Methodological studies